Dimension Bio
4 known investors
Dimension Bio is a biotechnology company developing regenerative therapeutics using its BioNidum platform, which combines materials science, 3D printing, and digital manufacturing to produce implantable and injectable biosynthetic scaffolds that promote tissue healing. Its products target clinical markets such as sports medicine, orthopedics, plastic and reconstructive surgery, aesthetics, dental, and neuro/spine, as well as cell delivery applications for conditions like liver failure and Type 1 diabetes.
Also known as Dimension Inx · Dimension Inx LLC
Founders & leadership
Investors · 4
Also in the syndicate · 2
Company profile
researched Aug 2026Dimension Bio is a Chicago, Illinois-based biotechnology company developing regenerative therapeutics intended to restore tissue and organ function lost to disease, trauma or aging. The company designs, develops and manufactures products built on BioNidum, a platform that combines materials science, 3D printing and digital manufacturing to engineer three-dimensional regenerative microenvironments that influence cell behavior, tissue organization and healing. The platform supports both implantable and injectable formats and can be used to make biosynthetic scaffolds alone or biohybrid constructs that combine scaffolds with therapeutic cells.
The company describes two application areas. The first is tissue regeneration and restoration, targeting clinical markets including sports medicine, orthopedics, plastic and reconstructive surgery, aesthetics, dental, and neuro/spine, with a pipeline developed both internally and with strategic partners. Its first commercial product, CMFlex, is a ready-to-use flexible ceramic synthetic bone graft for oral and maxillofacial indications that received FDA 510(k) clearance, announced in February 2023 as the first 3D-printed regenerative bone graft product cleared by the FDA. The second area is cell delivery and replacement, where BioNidum scaffolds are combined with therapeutic cells to create implantable cell therapies. The lead program is an implantable cell therapy for liver failure designed to provide immediate supplemental hepatic function, stabilizing patients through an acute crisis toward recovery or transplant; earlier exploratory work covered ovarian cells for infertility and islet cells for diabetes.
Leadership includes co-founder and CEO Caralynn Nowinski Collens, M.D., co-founder and CSO Ramille Shah, Ph.D., SVP of Manufacturing and Quality Operations Larry Weinstein, and SVP of Corporate Development Cole Johnson, Ph.D. The board of directors includes Collens, Shah, Rima Chakrabarti, Heidi Hagen and Amy Kruse, with Ayush Jain and Isaiah Reeves as observers. The company also lists a scientific advisory board (Jane Lebkowski, Lonnie Shea, Doris Taylor) and strategic advisors (Andy Christensen, Chris Ehrlich, Ritu Shah).
Founding story
Dimension Inx was formed around technology spun out of Northwestern University by Ramille Shah and Adam Jakus, with the premise of uniting biology and engineering to reimagine how biomaterials are used to treat patients. Early R&D showed the company's biomaterial scaffolds demonstrated rapid vascularization, resistance to foreign body response, and affinity for cells, which the company cites as the basis for expanding from biomaterial implants toward cell-containing tissue therapeutics.
Business model
The company develops and manufactures therapeutic products based on its own biomaterials and manufacturing platform, commercializing regulated medical products such as the FDA-cleared CMFlex bone graft while advancing internal therapeutic programs. It also works with biotech and medical device partners to co-develop products and solve materials problems, and has stated it operates a fully established GMP manufacturing process.
Revenue sources indicated in company materials include commercial sales of cleared medical products such as CMFlex, partner-based product co-development with biotech and medical device companies, and non-dilutive funding including a U.S. Department of Defense development award.
Traction
Milestones reported by the company include FDA 510(k) clearance and first surgical cases for CMFlex (2023), issuance of multiple additional patents (February 2024), preclinical data presentations on the BioNidum cell delivery system at the 2025 ASGCT meeting and on a liver failure treatment at AASLD 2025, formation of inaugural clinical and scientific advisory boards (November 2025), and commercialization resource awards from the ReGen Valley Tech Hub (August 2025). The company states it reached compelling preclinical data and a clear path to the clinic for its liver failure tissue therapeutic within a year of focusing on liver disease.
Latest developments
In 2025 the company rebranded from Dimension Inx to Dimension Bio (May 2025), presented preclinical data on the BioNidum therapeutic cell delivery system at ASGCT (May 2025), appointed Heidi Hagen to its board of directors (June 2025), received ReGen Valley Tech Hub commercialization resource awards for regulatory, manufacturing and reimbursement strategy (August 2025), rang the Nasdaq closing bell with Chicago Innovation Awards winners (August 2025), reported new preclinical results advancing BioNidum toward a restorative treatment for liver failure at AASLD 2025 (November 2025), and announced inaugural clinical and scientific advisory boards (November 2025).
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company positions itself as a biomaterials and cell delivery platform company in regenerative medicine, citing CMFlex as the first 3D-printed regenerative bone graft product cleared by the FDA and its liver program as a first-in-class implantable cell therapy. It has received third-party recognition including the 23rd Annual Chicago Innovation Awards (2024), finalist status in Fast Company's 2024 Innovation by Design Awards for CMFlex, and commercialization resource awards from the ARMI-led ReGen Valley Tech Hub.
The company attributes its differentiation to a materials-centric approach that enables biofunctionality without sacrificing manufacturability, with independent control over composition, architecture and microstructure that it states is not achievable with conventional manufacturing. It also cites an existing FDA-cleared biomaterial and established GMP manufacturing process as a foundation for advancing cell-based tissue therapeutics.
Technology
BioNidum is a bioinspired platform that fuses materials science, 3D printing and digital manufacturing to produce biosynthetic and biohybrid scaffolds. It provides independent control of material composition, three-dimensional architecture and microstructure, yielding an interconnected porous architecture that the company says promotes vascularization, cell infiltration, tissue integration and remodeling, while allowing tuning of mechanical performance, degradation behavior and surgical handling per indication. The platform is supported by a patent estate and proprietary manufacturing know-how spanning biomaterial compositions, 3D-printable inks, multi-material and biohybrid constructs, tissue repair applications and cell delivery systems. Earlier company materials describe a 3D-Painting materials design and manufacturing system and 'Tissue Papers' — thin, absorbent, paper-like constructs that can be cut, rolled, folded or sutured.
Go-to-market
The company pursues regulatory clearance for individual products (510(k) clearance for CMFlex) and commercial launch supported by venture funding, while building strategic partnerships with medical device and biotech organizations. It engages ecosystem programs such as the ReGen Valley Tech Hub for regulatory, manufacturing and reimbursement strategy support, and presents preclinical data at scientific meetings including ASGCT and AASLD.
Surgeons and clinicians in oral and maxillofacial, orthopedic, sports medicine, plastic and reconstructive, aesthetic, dental and neuro/spine settings; patients with tissue loss or organ failure, including liver failure and Type 1 diabetes; and biotech and medical device companies as co-development partners. Government agencies, including the U.S. Department of Defense, have funded specific development programs.
Geography
Headquartered in Chicago, Illinois. The company is engaged as a partner in the ReGen Valley Tech Hub in New Hampshire's Manchester-Nashua region, coordinated by ARMI.
History
The company was founded as Dimension Inx, with its platform technology spun out of Northwestern University by Adam Jakus, Ph.D. (then CTO) and Ramille Shah, Ph.D. (CSO), and led by CEO Caralynn Nowinski Collens, M.D. It closed a $3.175M Series Seed round in November 2020 to support commercial development and FDA clearance of implants for facial reconstruction and dental indications, and in May 2021 received a $240,000 U.S. Department of Defense award to develop a tracheal repair implant. In February 2023 the company announced a $12M Series A alongside FDA 510(k) clearance of CMFlex, and reported first surgical cases using CMFlex in October 2023. Additional patents were announced in February 2024, and the company won the 23rd Annual Chicago Innovation Awards in November 2024. By 2022 the platform had matured into BioNidum, and the company narrowed its therapeutic focus from ovarian and islet cell applications to liver disease. In May 2025 it rebranded from Dimension Inx to Dimension Bio to reflect a broader focus on tissue therapeutics and organ function restoration.
Risks & controversies
Company materials note that surgical approaches to tracheal defects carry up to 80% mortality and that its lead liver program remains preclinical, with regulatory, manufacturing and reimbursement pathways still being de-risked.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 14
launches, deals, and filingsSelected to receive Strategic Regulatory Services, Manufacturing Strategy and Reimbursement Strategy support to accelerate its implantable cell therapy for liver failure; engages as a partner in the ARMI-led Tech Hub.
Biotechnology veteran with cell therapy leadership experience joins the board as the company advances its liver failure program toward the clinic.
Company announced a new name reflecting expanded focus on tissue therapeutics and restoring organ function, with a lead program in liver failure.
Led by Prime Movers Lab with KdT Ventures, Revolution's Rise of the Rest Seed Fund, Solas BioVentures, Portal Innovation Ventures and Alumni Ventures; funds to advance organ restoration therapeutics, expand manufacturing and launch CMFlex.
$12M source ↗
CMFlex, a ready-to-use flexible ceramic for oral and maxillofacial indications, received FDA 510(k) clearance and is described as the first 3D-printed regenerative bone graft product cleared by the FDA.
$240,000 award from the U.S. Army Medical Research Acquisition Activity under the Peer Reviewed Medical Research Program (Award No. W81XWH-21-1-0291) supporting an 18-month project to develop a tracheal implant.
$240K source ↗
Round led by KdT Ventures with Better Ventures and Revolution's Rise of the Rest Seed Fund, to fund commercial development and FDA approval of first therapeutic implants for facial reconstruction and dental indications.
$3.2M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Dimension Biodimension.bio · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Dimension Bio do?
- Chicago biotech developing regenerative tissue therapeutics with its BioNidum 3D-printed biomaterial scaffold platform.
- Who founded Dimension Bio?
- Dimension Bio was founded by Caralynn Nowinski Collens, Ramille Shah, Adam Jakus.
- Who are Dimension Bio's investors?
- Dimension Bio's investors include HAWKTAIL, Prime Movers Lab.